Takeda transfers HPV vaccine license to Kaketsuken

Takeda transfers HPV vaccine license to Kaketsuken
Takeda transfers HPV vaccine license to Kaketsuken | Courtesy of
Takeda Pharmaceutical Company, Ltd., has recently transferred its license agreement for a vaccine for human papillomavirus (HPV) to Kaketsuken, the Chemo-Sero-Therapeutic Research Institute.

Takeda started the agreement with the Japan Health HS Foundation in October 2010. Upon the agreement, Takeda began preclinical development for the HPV vaccine that could prevent cervical cancer. Now, Kaketsuken will be responsible for further developments with the HPV vaccine.

Tadahito Kanda, an expert instrumental in HPV vaccine research projects at the National Institute of Infectious Diseases (NID) of Japan, was the inventor of the vaccine. He now works with the RIKEN Institute to further his studies.

"Takeda welcomes Kaketsuken's interest in the development of this vaccine candidate as a potential new option to fight HPV," Takeda President Rajeev Venkayya said. "Through these agreements and our ongoing work on other vaccine programs to address unmet medical needs, Takeda continues to contribute to public health in Japan and around the world."   

For over 60 years, Takeda has provided vaccines to the citizens of Japan. The global vaccine business branch of Takeda began in January 2012, and now the company is concentrating on solving some of the most challenging health concerns in the world, including investigating vaccines for norovirus and dengue.

Organizations in this Story

Kaketsuken Takeda Pharmaceutical Company

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.